The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment.

Pham, H Phuong T; Gupta, Resmi; Lindsey, J William

Pham, H Phuong T; Gupta, Resmi; Lindsey, J William.

Afiliação

Pham HPT; Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Gupta R; Division of Clinical and Translational Sciences, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Lindsey JW; Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: john.w.lindsey@uth.tmc.edu.

Mult Scler Relat Disord ; 56: 103282, 2021 Nov.

Article em En | MEDLINE | ID: mdl-34624646

Assuntos

Infecções por Vírus Epstein-Barr; Herpesvirus Humano 4; Anticorpos Monoclonais Humanizados; Infecções por Vírus Epstein-Barr/complicações; Infecções por Vírus Epstein-Barr/tratamento farmacológico; Humanos; Imunidade Celular; Leucócitos Mononucleares

Palavras-chave

B cell depletion; Epstein-Barr virus; Multiple sclerosis; Ocrelizumab; T lymphocytes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Herpesvirus Humano 4 / Infecções por Vírus Epstein-Barr Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google